Glaxosmithkline Pharmaceuticals Reports Positive PAT Growth in Q1 FY25, Advised to Hold Stock

Glaxosmithkline Pharmaceuticals, a leading player in the pharmaceutical industry, recently announced its financial results for the quarter ending March 2024. The company’s stock has been given a ‘Hold’ call by MarketsMOJO.

According to the financial report, Glaxosmithkline Pharmaceuticals has shown a flat performance in the quarter, with a score of 3 out of 5, which is an improvement from the previous quarter’s score of 1. The company’s Profit After Tax (PAT) for the half-yearly period has seen a significant growth of 52.64% year on year, reaching Rs 375.09 crore. This indicates a positive trend in the near term for the company’s profitability.

However, the company’s Net Sales for the quarter have fallen by -5.6% compared to the average Net Sales of the previous four quarters. This decline in sales has resulted in a negative trend in the near term. Additionally, Glaxosmithkline Pharmaceuticals’ Debtors Turnover Ratio for the half-yearly period is at its lowest in the last five periods, standing at 15.55 times. This suggests that the company’s pace of settling its debtors has slowed down.

Despite these challenges, Glaxosmithkline Pharmaceuticals remains a strong player in the pharma industry, with a large market capitalization. The company’s financial performance in the quarter ending March 2024 may have been flat, but its PAT growth and overall score improvement show potential for future growth. Investors are advised to hold their positions in the company’s stock, as recommended by MarketsMOJO.